1 in 7

Teva Pharmaceuticals

Invisible illness

Migraine can be debilitating and life-limiting. As well as a severe headache, symptoms include nausea, dizziness, visual phenomena called aura, and sensitivity to light.

Migraine is a mostly ‘invisible’ condition, and that contributes to the public’s misunderstanding of it. Many presume that it is little more than a bad headache.


Introducing Ajovy

Ajovy is a new drug from Teva Pharmaceuticals that reduces the frequency and severity of migraine symptoms.

To build an intelligent communications strategy for Ajovy, our first step was a grounding in research.

We discovered that 1 in 7 people in Ireland experience migraine, a finding that drove our campaign.

Migraine made visible

Over the course of a year, 360 carried out a campaign of public affairs, stakeholder engagement, and creative content activities, including a social media campaign and virtual reality experience.

 The 1 in 7 campaign culminated in a public activation on Dublin’s Samuel Beckett Bridge, where a hundred people stood shoulder to shoulder, representing the 1 in 7 people who suffer from migraine.

Making a difference

360’s work captured the attention of the public and healthcare practitioners, raising awareness of migraine and the potential of Ajovy for treatment.

Like what you see?

Get in touch today to see how we can use intelligent communications to bring your message to life.

See More Work